{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:24:09Z","timestamp":1791357849038,"version":"4.3.1"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.phrs.2020.105020","type":"journal-article","created":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T12:25:58Z","timestamp":1592310358000},"page":"105020","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":70,"special_numbering":"C","title":["Efficacy and safety of HIF prolyl-hydroxylase inhibitor vs epoetin and darbepoetin for anemia in chronic kidney disease patients not undergoing dialysis: A network meta-analysis"],"prefix":"10.1016","volume":"159","author":[{"given":"Qiyan","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huisheng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luying","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruojun","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinwen","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yishan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu Ning","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9888","key":"10.1016\/j.phrs.2020.105020_bib0005","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S0140-6736(13)60687-X","article-title":"Chronic kidney disease: global dimension and perspectives","volume":"382","author":"Jha","year":"2013","journal-title":"LANCET"},{"issue":"17","key":"10.1016\/j.phrs.2020.105020_bib0010","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1001\/jama.298.17.2038","article-title":"Prevalence of chronic kidney disease in the United States","volume":"298","author":"Coresh","year":"2007","journal-title":"JAMA"},{"issue":"90006","key":"10.1016\/j.phrs.2020.105020_bib0015","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/ndt\/17.suppl_6.2","article-title":"A rationale for an individualized haemoglobin target","volume":"17","author":"Muirhead","year":"2002","journal-title":"Nephrol. Dial. Transplant."},{"issue":"4","key":"10.1016\/j.phrs.2020.105020_bib0020","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1681\/ASN.2005090997","article-title":"Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients","volume":"17","author":"Regidor","year":"2006","journal-title":"J. Am. Soc. Nephrol."},{"issue":"Suppl 2(6)","key":"10.1016\/j.phrs.2020.105020_bib0025","first-page":"i2","article-title":"Anaemia management prior to dialysis: cardiovascular and cost-benefit observations","volume":"18","author":"Collins","year":"2003","journal-title":"Nephrol. Dial. Transplant."},{"issue":"2","key":"10.1016\/j.phrs.2020.105020_bib0030","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2215\/CJN.02590706","article-title":"Epoetin alfa once every 2 weeks is effective for initiation of treatment of anemia of chronic kidney disease","volume":"2","author":"Benz","year":"2007","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"12","key":"10.1016\/j.phrs.2020.105020_bib0035","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1056\/NEJMoa1005109","article-title":"Erythropoietic response and outcomes in kidney disease and type 2 diabetes","volume":"363","author":"Solomon","year":"2010","journal-title":"New England J. Med."},{"issue":"6","key":"10.1016\/j.phrs.2020.105020_bib0040","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/ki.2008.295","article-title":"Secondary analysis of the CHOIR trial epoetin-\u03b1 dose and achieved hemoglobin outcomes","volume":"74","author":"Szczech","year":"2008","journal-title":"Kidney Int."},{"key":"10.1016\/j.phrs.2020.105020_bib0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2019.172532","article-title":"JTZ-951 (enarodustat), a hypoxia-inducibe factor prolyl hydroxylase inhibitor, stabilizes HIF-alpha protein and induces erythropoiesis without effects on the function of vascular endothelial growth factor","volume":"859","author":"Fukui","year":"2019","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.phrs.2020.105020_bib0050","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa062276","article-title":"Normalization of hemoglobin level in patients with chronic kidney disease and anemia","volume":"355","author":"Drueke","year":"2006","journal-title":"New England J. Med."},{"issue":"20","key":"10.1016\/j.phrs.2020.105020_bib0055","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1056\/NEJMoa065485","article-title":"Correction of anemia with epoetin alfa in chronic kidney disease","volume":"355","author":"Singh","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.phrs.2020.105020_bib0060","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.molcel.2010.09.022","article-title":"Hypoxia-inducible factors and the response to hypoxic stress","volume":"40","author":"Majmundar","year":"2010","journal-title":"Mol. Cell"},{"issue":"7521","key":"10.1016\/j.phrs.2020.105020_bib0065","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1136\/bmj.331.7521.897","article-title":"Simultaneous comparison of multiple treatments: combining direct and indirect evidence","volume":"331","author":"Caldwell","year":"2005","journal-title":"BMJ Br. Med. J."},{"key":"10.1016\/j.phrs.2020.105020_bib0070","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jclinepi.2016.11.015","article-title":"Additional considerations are required when preparing a protocol for a systematic review with multiple interventions","volume":"83","author":"Chaimani","year":"2017","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.phrs.2020.105020_bib0075","unstructured":"Julian Higgins, Sally Green, Cochrane handbook for systematic reviews of interventions, The Cochrane Collaboration."},{"issue":"7","key":"10.1016\/j.phrs.2020.105020_bib0080","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0099682","article-title":"Evaluating the quality of evidence from a network meta-analysis","volume":"9","author":"Salanti","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2020.105020_bib0085","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.cct.2015.03.005","article-title":"A multilevel approach to network meta-analysis within a frequentist framework","volume":"42","author":"Greco","year":"2015","journal-title":"Contemp. Clin. Trials"},{"issue":"2","key":"10.1016\/j.phrs.2020.105020_bib0090","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"J. Clin. Epidemiol."},{"issue":"2","key":"10.1016\/j.phrs.2020.105020_bib0095","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/jrsm.1044","article-title":"Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies","volume":"3","author":"Higgins","year":"2012","journal-title":"Res. Synth. Methods"},{"issue":"10","key":"10.1016\/j.phrs.2020.105020_bib0100","article-title":"Graphical tools for network meta-analysis in STATA","volume":"8","author":"Anna","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.phrs.2020.105020_bib0105","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s11255-013-0512-1","article-title":"A randomised single-blind study to improve health-related quality of life by treating anaemia of chronic kidney disease with Aranesp\u00ae (darbepoetin alfa) in older people: STIMULATE","volume":"46","author":"Roger","year":"2014","journal-title":"Int. Urol. Nephrol."},{"issue":"5","key":"10.1016\/j.phrs.2020.105020_bib0110","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.kint.2016.07.019","article-title":"Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease","volume":"90","author":"Pergola","year":"2016","journal-title":"Kidney Int."},{"issue":"4","key":"10.1016\/j.phrs.2020.105020_bib0115","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1681\/ASN.2014111139","article-title":"Four-week studies of oral hypoxia-inducible factor-prolyl hydroxylase inhibitor GSK1278863 for treatment of anemia","volume":"27","author":"Holdstock","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"issue":"6","key":"10.1016\/j.phrs.2020.105020_bib0120","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1053\/j.ajkd.2015.11.021","article-title":"A novel hypoxia-inducible factor\u2212Prolyl hydroxylase inhibitor (GSK1278863) for anemia in CKD: a 28-Day, phase 2A randomized trial","volume":"67","author":"Brigandi","year":"2016","journal-title":"Am. J. Kidney Dis."},{"issue":"1","key":"10.1016\/j.phrs.2020.105020_bib0125","doi-asserted-by":"crossref","first-page":"28","DOI":"10.2215\/CJN.02510218","article-title":"Effects of molidustat in the treatment of anemia in CKD","volume":"14","author":"Macdougall","year":"2019","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"3","key":"10.1016\/j.phrs.2020.105020_bib0130","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1053\/j.ajkd.2018.10.006","article-title":"Treatment of anemia with darbepoetin prior to dialysis initiation and clinical outcomes: analyses from the trial to reduce cardiovascular events with aranesp therapy (TREAT)","volume":"73","author":"Mc Causland","year":"2019","journal-title":"Am. J. Kidney Dis."},{"issue":"1","key":"10.1016\/j.phrs.2020.105020_bib0135","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/ckj\/sfy013","article-title":"Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants with chronic kidney disease","volume":"12","author":"Holdstock","year":"2019","journal-title":"Clin. Kidney J."},{"issue":"6","key":"10.1016\/j.phrs.2020.105020_bib0140","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1159\/000500232","article-title":"Outcomes of desidustat treatment in people with anemia and chronic kidney disease: a phase 2 study","volume":"49","author":"Parmar","year":"2019","journal-title":"Am. J. Nephrol."},{"issue":"6","key":"10.1016\/j.phrs.2020.105020_bib0145","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1007\/s12325-019-00943-4","article-title":"Roxadustat treatment of chronic kidney disease-associated anemia in Japanese patients not on dialysis: a phase 2, randomized, double-blind, placebo-controlled trial","volume":"36","author":"Akizawa","year":"2019","journal-title":"Adv. Ther."},{"issue":"Supplement 1","key":"10.1016\/j.phrs.2020.105020_bib0150","volume":"31","author":"Macdougall","year":"2016","journal-title":"Nephrol. Dial. Transplant."},{"issue":"5","key":"10.1016\/j.phrs.2020.105020_bib0155","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1159\/000464476","article-title":"Clinical trial of vadadustat in patients with anemia secondary to stage 3 or 4 chronic kidney disease","volume":"45","author":"Martin","year":"2017","journal-title":"Am. J. Nephrol."},{"issue":"11","key":"10.1016\/j.phrs.2020.105020_bib0160","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa1813599","article-title":"Roxadustat for anemia in patients with kidney disease not receiving dialysis","volume":"381","author":"Chen","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.phrs.2020.105020_bib0165","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1093\/ndt\/gfv302","article-title":"Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients","volume":"30","author":"Besarab","year":"2015","journal-title":"Nephrol. Dial. Transplant."},{"issue":"2","key":"10.1016\/j.phrs.2020.105020_bib0170","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1159\/000496929","article-title":"Randomized trial of enarodustat in patients with chronic kidney disease followed by long-term trial","volume":"49","author":"Akizawa","year":"2019","journal-title":"Am. J. Nephrol."},{"issue":"8","key":"10.1016\/j.phrs.2020.105020_bib0175","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1093\/ndt\/gfx011","article-title":"Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China","volume":"32","author":"Chen","year":"2017","journal-title":"Nephrol. Dial. Transplant."},{"issue":"1","key":"10.1016\/j.phrs.2020.105020_bib0180","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s10238-010-0100-y","article-title":"Anemia correction by erythropoietin reduces BNP levels, hospitalization rate, and NYHA class in patients with cardio-renal anemia syndrome","volume":"11","author":"Palazzuoli","year":"2011","journal-title":"Clin. Exp. Med."},{"issue":"6","key":"10.1016\/j.phrs.2020.105020_bib0185","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/S0272-6386(89)80149-0","article-title":"The use of recombinant human erythropoietin in the correction of anemia in predialysis patients and its effect on renal function: a double-blind, placebo-controlled trial","volume":"15","author":"Kleinman","year":"1989","journal-title":"Am. J. Kidney Dis."},{"issue":"4","key":"10.1016\/j.phrs.2020.105020_bib0190","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.ahj.2007.07.022","article-title":"Effects of \u03b2-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome","volume":"154","author":"Palazzuoli","year":"2007","journal-title":"Am. Heart J."},{"issue":"2","key":"10.1016\/j.phrs.2020.105020_bib0195","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1046\/j.1523-1755.2001.060002741.x","article-title":"Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency","volume":"60","author":"Locatelli","year":"2001","journal-title":"Kidney Int."},{"issue":"4","key":"10.1016\/j.phrs.2020.105020_bib0200","first-page":"279","article-title":"KDIGO clinical practice guideline for anemia in chronic kidney disease","volume":"2","author":"Jjv","year":"2012","journal-title":"Kidney Int. Suppl."},{"issue":"7","key":"10.1016\/j.phrs.2020.105020_bib0205","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/nrneph.2015.82","article-title":"Anaemia in kidney disease: harnessing hypoxia responses for therapy","volume":"11","author":"Koury","year":"2015","journal-title":"Nat. Rev. Nephrol."},{"issue":"10","key":"10.1016\/j.phrs.2020.105020_bib0210","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1161\/CIRCULATIONAHA.109.922427","article-title":"Loss of hypoxia-inducible factor prolyl hydroxylase activity in cardiomyocytes phenocopies ischemic cardiomyopathy","volume":"122","author":"Moslehi","year":"2010","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.phrs.2020.105020_bib0215","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1056\/NEJMoa073123","article-title":"A gain-of-function mutation in the HIF2A gene in familial erythrocytosis","volume":"358","author":"Percy","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.phrs.2020.105020_bib0220","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0111838","article-title":"Mimicking hypoxia to treat anemia: HIF-stabilizer BAY 85-3934 (Molidustat) stimulates erythropoietin production without hypertensive effects","volume":"9","author":"Flamme","year":"2014","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.phrs.2020.105020_bib0225","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1172\/JCI38499","article-title":"HIF-2\u03b1, but not HIF-1\u03b1, promotes iron absorption in mice","volume":"119","author":"Mastrogiannaki","year":"2009","journal-title":"J. Clin. Invest."},{"issue":"9","key":"10.1016\/j.phrs.2020.105020_bib0230","article-title":"Hepcidin is involved in iron regulation in the ischemic brain","volume":"6","author":"Hui","year":"2011","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.phrs.2020.105020_bib0235","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1517\/13543776.2010.510836","article-title":"Prolyl hydroxylase domain-containing protein inhibitors as stabilizers of hypoxia-inducible factor: small molecule-based therapeutics for anemia","volume":"20","author":"Yan","year":"2010","journal-title":"Expert Opin. Ther. Pat."},{"issue":"32","key":"10.1016\/j.phrs.2020.105020_bib0240","doi-asserted-by":"crossref","first-page":"20055","DOI":"10.1074\/jbc.272.32.20055","article-title":"Oxygen-regulated transferrin expression is mediated by hypoxia-inducible factor-1","volume":"272","author":"Rolfs","year":"1997","journal-title":"J. Biol. Chem."},{"issue":"21","key":"10.1016\/j.phrs.2020.105020_bib0245","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1093\/nar\/27.21.4223","article-title":"HIF-1-mediated activation of transferrin receptor gene transcription by iron chelation","volume":"27","author":"Laura","year":"1999","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"10.1016\/j.phrs.2020.105020_bib0250","first-page":"24","article-title":"Two to tango: regulation of mammalian iron metabolism","volume":"142","author":"Hentze","year":"2010","journal-title":"Physiol. Rev."},{"issue":"4","key":"10.1016\/j.phrs.2020.105020_bib0255","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1152\/physrev.00008.2013","article-title":"Systemic iron homeostasis","volume":"93","author":"Ganz","year":"2013","journal-title":"Physiol. Rev."},{"issue":"14","key":"10.1016\/j.phrs.2020.105020_bib0260","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.2174\/0929867324666170316120538","article-title":"Role of hepcidin-25 in chronic kidney disease: anemia and beyond","volume":"24","author":"Ueda","year":"2017","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.phrs.2020.105020_bib0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104747","article-title":"Roxadustat (FG-4592) treatment for anemia in dialysis-dependent (DD) and not dialysis-dependent (NDD) chronic kidney disease patients: a systematic review and meta-analysis","volume":"155","author":"Liu","year":"2020","journal-title":"Pharmacol. Res."},{"issue":"12","key":"10.1016\/j.phrs.2020.105020_bib0270","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1007\/s11255-018-1940-8","article-title":"Effect of daprodustat on anemia in patients with chronic kidney disease: a meta-analysis","volume":"50","author":"Xie","year":"2018","journal-title":"Int. Urol. Nephrol."},{"key":"10.1016\/j.phrs.2020.105020_bib0275","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.2147\/DDDT.S175887","article-title":"The role of hypoxia-inducible factor stabilizers in the treatment of anemia in patients with chronic kidney disease","volume":"12","author":"Zhong","year":"2018","journal-title":"Drug Des Dev Ther."},{"issue":"1","key":"10.1016\/j.phrs.2020.105020_bib0280","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1053\/j.ajkd.2014.12.012","article-title":"Mortality risk of darbepoetin alfa versus epoetin alfa in patients with CKD: systematic review and meta-analysis","volume":"66","author":"Wilhelm-Leen","year":"2015","journal-title":"Am. J. Kidney Dis."},{"issue":"3","key":"10.1016\/j.phrs.2020.105020_bib0285","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1159\/000330355","article-title":"The role of statins in chronic kidney disease","volume":"34","author":"Kalaitzidis","year":"2011","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.phrs.2020.105020_bib0290","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.phrs.2014.06.011","article-title":"Statins in chronic kidney disease and kidney transplantation","volume":"88","author":"Kassimatis","year":"2014","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2020.105020_bib0295","doi-asserted-by":"crossref","DOI":"10.1053\/j.ajkd.2016.12.011","article-title":"Hypoxia-inducible factor prolyl hydroxylase inhibitors: a potential new treatment for anemia in patients with CKD","author":"Gupta","year":"2017","journal-title":"Am. J. Kidney Dis."},{"issue":"21","key":"10.1016\/j.phrs.2020.105020_bib0300","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","article-title":"A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease","volume":"361","author":"Pfeffer","year":"2009","journal-title":"N. Engl. J. Med."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661820313281?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661820313281?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:22:54Z","timestamp":1760912574000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661820313281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":60,"alternative-id":["S1043661820313281"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2020.105020","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of HIF prolyl-hydroxylase inhibitor vs epoetin and darbepoetin for anemia in chronic kidney disease patients not undergoing dialysis: A network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2020.105020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105020"}}